Compile Data Set for Download or QSAR
Report error Found 24 Enz. Inhib. hit(s) with all data for entry = 10879
TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576132(WO2021069705, Compound 2)
Affinity DataIC50: 254nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576137(WO2021069705, Compound 7)
Affinity DataIC50: 324nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576135(WO2021069705, Compound 5)
Affinity DataIC50: 339nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576152(WO2021069705, Compound 22)
Affinity DataIC50: 393nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576133(WO2021069705, Compound 3)
Affinity DataIC50: 400nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576153(WO2021069705, Compound 23)
Affinity DataIC50: 464nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576136(WO2021069705, Compound 6)
Affinity DataIC50: 467nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576138(WO2021069705, Compound 8)
Affinity DataIC50: 468nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576134(WO2021069705, Compound 4)
Affinity DataIC50: 483nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576147(WO2021069705, Compound 17)
Affinity DataIC50: 514nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576150(WO2021069705, Compound 20)
Affinity DataIC50: 550nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576148(WO2021069705, Compound 18)
Affinity DataIC50: 552nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576149(WO2021069705, Compound 19)
Affinity DataIC50: 576nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576139(WO2021069705, Compound 9)
Affinity DataIC50: 617nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576151(WO2021069705, Compound 21)
Affinity DataIC50: 622nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576140(WO2021069705, Compound 10)
Affinity DataIC50: 763nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576146(WO2021069705, Compound 16)
Affinity DataIC50: 817nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576145(WO2021069705, Compound 15)
Affinity DataIC50: 902nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576143(WO2021069705, Compound 13)
Affinity DataIC50: 944nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576142(WO2021069705, Compound 12)
Affinity DataIC50: 960nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576131(WO2021069705, Compound 1)
Affinity DataIC50: 1.04E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576141(WO2021069705, Compound 11)
Affinity DataIC50: 1.23E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576144(WO2021069705, Compound 14)
Affinity DataIC50: 1.42E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705

TargetProtein cereblon(Human)
Monte Rosa Therapeutics

WIPO
LigandPNGBDBM576154(WO2021069705, Compound 24)
Affinity DataIC50: 1.59E+3nMAssay Description:Compound activity was monitored in a fluorescence polarization (FP) homogeneous assay using 1 -[5-({2-[2-(2-{[2-(2,6-dioxopiperidin-3-yl)-1 ,3-dioxo-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2022
Entry Details
WIPO WO2021069705